cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Arvinas Inc
6 own
4 watching
Current Price
$0
$-0.64
(-2.66%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,282.13M
52-Week High
52-Week High
58.58
52-Week Low
52-Week Low
21.21
Average Volume
Average Volume
0.44M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,282.13M
icon52-Week High58.58
icon52-Week Low21.21
iconAverage Volume0.44M
iconDividend Yield--
iconP/E Ratio--
What does the Arvinas Inc do?
Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has a collaboration with Bayer AG to develop novel proteolysis-targeting chimera candidates for humans and plants. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Read More
How much money does Arvinas Inc make?
News & Events about Arvinas Inc.
Globe Newswire
1month ago
Multiple vepdegestrant (ARV-471) studies enrolling globally, including Phase 1, 2, and 3 studies Preliminary data from the Phase 1b combination trial of vepdegestrant + palbociclib suggests potential clinical benefit in a heavily pretreated patient population NEW HAVEN, Conn., May 05, 2023 (GLOBE ...
PR Newswire
1month ago
Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform...
Ticker Report
1month ago
Arvinas, Inc. (NASDAQ:ARVN Get Rating) has been given a consensus rating of Moderate Buy by the eighteen brokerages that are covering the company, Marketbeat reports. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The...
Accesswire
2 months ago
Oerth's unique PROTAC® protein degradation technology is expected to be a new, game-changing generation of more sustainable crop protection products / The agreement recommits to the combination of Oerth Bio's specialized expertise designing PROTAC® degraders for agriculture with...
Zolmax
3 months ago
Arvinas, Inc. (NASDAQ:ARVN Get Rating) Equities researchers at HC Wainwright issued their Q2 2023 earnings estimates for Arvinas in a research report issued to clients and investors on Friday, February 24th. HC Wainwright analyst A. Fein forecasts that the company will post earnings ...
Frequently Asked Questions
Frequently Asked Questions
What is Arvinas Inc share price today?
plus_minus_icon
Can Indians buy Arvinas Inc shares?
plus_minus_icon
How can I buy Arvinas Inc shares from India?
plus_minus_icon
Can Fractional shares of Arvinas Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Arvinas Inc stocks?
plus_minus_icon
What is today’s traded volume of Arvinas Inc?
plus_minus_icon
What is today’s market capitalisation of Arvinas Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Arvinas Inc?
plus_minus_icon
What percentage is Arvinas Inc down from its 52-Week High?
plus_minus_icon
What percentage is Arvinas Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.64
(-2.66%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
$21.98
$-0.12 (-0.54 %)
89bio Inc
89bio Inc
$20.42
$0.26 (1.29 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$20.96
$0.00 (0.00 %)
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc
$29.21
$0.64 (2.26 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
$21.98
$-0.12 (-0.54 %)
89bio Inc
89bio Inc
$20.42
$0.26 (1.29 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$20.96
$0.00 (0.00 %)
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc
$29.21
$0.64 (2.26 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00